Business Wire

Hypernative Raises $40M Series B to Remove Security Barriers to Web3 Mass Adoption

10.6.2025 14:30:00 CEST | Business Wire | Press Release

Share

Hypernative, the leading provider of real-time threat prevention in Web3, today announced a $40 million Series B funding round co-led by Ten Eleven Ventures and Ballistic Ventures, with participation from StepStone Group, and existing investors boldstart ventures and IBI Tech Fund.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610162307/en/

Hypernative team

The funds will support the expansion of the company’s offering to include fraud prevention and wallet-level transaction protection—key steps toward building an end-to-end security platform for Web3. They will also fuel improvements to AI models through wider investment into high-quality training data, and support team growth to provide expert-driven risk analysis and customer support.

In 2024, Hypernative detected over $2.2 billion of losses from hacks, exploits, phishing, and fraud—a 22% jump from the previous year. Following the $1.4 billion Bybit hack in February, the industry is on track for another record-breaking year of security failures.

Hypernative uses AI-powered detection to respond to threats in real time, helping secure transactions and build trust across the Web3 ecosystem. The platform, used by over 200 customers to help protect more than $100 billion in assets, continues to evolve through ongoing integrations. With recent expansion into wallets, exchanges, and payment providers, Hypernative is contributing to a more unified approach to Web3 security.

Gal Sagie, Co-founder and CEO of Hypernative, said: “Web3 is at an inflection point: clear regulation is finally emerging, and institutional adoption is accelerating led by stablecoins and tokenized assets. But security remains the biggest blocker to mass adoption—and Hypernative is on a mission to close that gap.”

The funding round follows a number of exciting milestones for the company:

  • Over the past year, Hypernative has more than doubled its network coverage to 60+ chains, including Solana and THORChain, enhancing security with hundreds of detectors to identify the industry's largest set of risks across not just security, but also financial, compliance and governance.
  • The launch of Guardian, a real-time transaction security solution that protects against blind signing by simulating the outcome of every transaction before it is approved.
  • Additionally, the team launched new ways of integrating Hypernative threat intelligence directly into a project's contracts or prior to block inclusion with sequencer integrations, frontend apps, liquidity pools, staking, and more.

“As leading cybersecurity investors, Ten Eleven recognizes how critical a robust security layer is to furthering adoption of Web3 technologies. Hypernative’s cohesive approach to real-time threat detection and response positions it as a foundational player in the future of decentralized ecosystems. That’s why we are proud to lead the Series B round and look forward to supporting the company through its next stage of growth,” said Mark Hatfield, Co-founder and General Partner of Ten Eleven Ventures.

"Hypernative is tackling the single greatest barrier to Web3’s mainstream future: trust. As attacks grow more sophisticated, the need for proactive, real-time security has never been more urgent," said Barmak Meftah, Co-founder and General Partner, Ballistic Ventures. "What Gal and the Hypernative team have built is not just innovative, it’s foundational to the next era of the internet. We're proud to back them as they scale their platform, expand their AI capabilities, and secure the path to mass adoption."

Hypernative's customer base ranges from chains, wallets, and protocols to exchanges, asset managers, and stablecoin issuers. More than 200 Web3 projects already rely on Hypernative for their security, with Aptos, Ethereum, Morpho, Movement, Sonic, Star Atlas, Wintermute, and ZKsync joining the list earlier this year.

To learn more about how Hypernative stops Web3 threats before they do any damage, visit: https://hypernative.io

About Hypernative

Hypernative is a real-time monitoring, risk detection and automated response solution that identifies threats with high accuracy and gives customers precious minutes to respond before exploits can do damage. The platform tracks both onchain and offchain data sources and uses battle-tested, sophisticated machine learning models, heuristics, simulations, and graph-based detections to identify over 300 risk types, from smart contract hacks and bridge security incidents to frontend compromises, market manipulations and private key theft. For more information, visit hypernative.io.

About Ten Eleven Ventures

Ten Eleven Ventures is the original cybersecurity-focused, global and stage-agnostic investment firm. The firm finds, invests in and helps grow top cybersecurity companies addressing critical digital security needs, tapping its team, network and experience to help build successful businesses. Since its founding, Ten Eleven Ventures has raised over $US1 billion and made over 60 cybersecurity investments across stages worldwide, including KnowBe4, Darktrace, Axis Security, Twistlock, Verodin, Cylance and Ping Identity. For more information, please visit 1011vc.com.

About Ballistic Ventures

Ballistic Ventures is a venture capital firm solely dedicated to early-stage cybersecurity and cyber-related companies. The partners have spent their entire careers defending against every cyber threat conceivable. Members of the firm have founded, operated, and funded over 100 successful cybersecurity firms – including Abnormal Security, AlienVault, ArcSight, Fortify, Mandiant, and Shape Security – led over 10,000 security professionals globally, and have 40+ years of experience in venture capital. Our experience provides entrepreneurs impactful support from people focused on the same mission. Our networks and relationships open doors for our founders. Learn more at ballisticventures.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610162307/en/

Contacts

Hypernative Press Contact:
Oliver Senchal
oliver@hypernative.io

Ten Eleven Ventures Press Contact:
Monsy Carlo
monsy@1011vc.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye